When A Hold Is The Best Investing Advice: Neuropathix Inc (NPTX)


Neuropathix Inc (NPTX) is a socially responsible pain management life sciences company, it closed down -6.38% on Friday at $0.0880. Shares of NPTX dropped over -24.20% in the last month; with an average volume for the month over 48.55K shares. If we look at three-month performance, NPTX stock falls over -32.98% while the average volume for the stock was 32.46K. The last 12 months have been bad for the stock with over -89.89% fall in stock price, reaching a high of $1.0200. There is no latest news revealed or publicized by the NPTX. These are the most recent news revealed by the Company.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


Recent Highlights

On May 06, 2021, Neuropathix, Inc. (OTCQB: NPTX) revealed that a study was conducted by researchers at Neuropathix, Inc. (OTCQB: NPTX), and the Lewis Katz School of Medicine at Temple University. The researchers demonstrated that in mice Neuropathix’s patented compound KLS-13019 prevents and reverses chemotherapy-induced peripheral neuropathy (CIPN).

Jan. 25, 2021, Neopathix, Inc. (OTCQB: NPTX), notified its shareholders of recent initiatives and corporate updates in a letter sent to shareholders.

Jan. 12, 2021, Neopathix, Inc. (OTCQB: NPTX) has announced the appointment of pain management expert Dr. Daniel Richman to the Company’s Board of Advisors.

About Neuropathix, Inc. (OTCQB: NPTX)

The primary focus of Neuropathix, Inc. is the research and development of medicines to treat patients with major unmet medical needs through socially responsible pain management and neuroprotective treatments.



Please enter your comment!
Please enter your name here